Index
RUT
P/E
-
EPS (ttm)
-0.29
Insider Own
3.61%
Shs Outstand
51.64M
Perf Week
5.48%
Market Cap
437.43M
Forward P/E
-
EPS next Y
-
Insider Trans
-2.73%
Shs Float
49.78M
Perf Month
1.07%
Enterprise Value
849.53M
PEG
-
EPS next Q
0.11
Inst Own
86.24%
Perf Quarter
-25.31%
Income
-8.60M
P/S
0.65
EPS this Y
-66.01%
Inst Trans
4.93%
Perf Half Y
-9.89%
Sales
676.80M
P/B
0.84
EPS next Y
-
ROA
-0.63%
Perf YTD
-31.47%
Book/sh
10.10
P/C
2.71
EPS next 5Y
-
ROE
-1.60%
52W High
14.06 -39.76%
Perf Year
72.15%
Cash/sh
3.13
P/FCF
3.23
EPS past 3/5Y
- -30.38%
ROIC
-0.78%
52W Low
4.71 79.83%
Perf 3Y
-4.51%
Dividend Est.
-
EV/EBITDA
5.12
Sales past 3/5Y
-12.72% -13.74%
Gross Margin
44.44%
Volatility
7.45% 4.84%
Perf 5Y
-86.11%
Dividend TTM
-
EV/Sales
1.26
EPS Y/Y TTM
126.18%
Oper. Margin
10.52%
ATR (14)
0.46
Perf 10Y
-76.72%
Dividend Ex-Date
-
Quick Ratio
2.08
Sales Y/Y TTM
-29.89%
Profit Margin
-1.27%
RSI (14)
52.08
Dividend Gr. 3/5Y
- -
Current Ratio
4.29
EPS Q/Q
-94.10%
SMA20
2.39%
Beta
2.33
Payout
0.00%
Debt/Eq
1.10
Sales Q/Q
-29.75%
SMA50
-0.82%
Rel Volume
1.67
Prev Close
8.23
Employees
900
LT Debt/Eq
1.10
SMA200
-11.77%
Avg Volume
843.65K
Price
8.47
IPO
Nov 15, 2006
Option/Short
Yes / Yes
Trades
Volume
1,407,265
Change
2.92%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-30-24 Initiated H.C. Wainwright
Buy
$15
Aug-22-24 Initiated Rodman & Renshaw
Buy
$16
Mar-07-24 Upgrade The Benchmark Company
Hold → Buy
$5
Nov-20-23 Resumed JP Morgan
Underweight
Aug-29-23 Downgrade The Benchmark Company
Buy → Hold
Apr-10-23 Upgrade The Benchmark Company
Hold → Buy
$22
Mar-17-23 Downgrade JP Morgan
Neutral → Underweight
$23 → $9
Nov-10-22 Downgrade The Benchmark Company
Buy → Hold
Apr-29-22 Downgrade Cantor Fitzgerald
Overweight → Neutral
Jan-20-22 Upgrade The Benchmark Company
Hold → Buy
$77
Nov-08-21 Downgrade The Benchmark Company
Buy → Hold
May-05-21 Downgrade Argus
Buy → Hold
Apr-07-21 Initiated The Benchmark Company
Buy
$150
Feb-24-21 Upgrade Chardan Capital Markets
Neutral → Buy
$112
Feb-19-21 Downgrade Chardan Capital Markets
Buy → Neutral
$112
Jan-08-21 Downgrade Wells Fargo
Overweight → Equal Weight
$110
Sep-14-20 Resumed JP Morgan
Neutral
$103
Jul-31-20 Reiterated Chardan Capital Markets
Buy
$86 → $112
Sep-12-19 Initiated Guggenheim
Buy
Sep-04-19 Upgrade Wells Fargo
Market Perform → Outperform
Show Previous Ratings
May-01-26 08:30AM
03:19AM
Apr-30-26 05:20PM
04:30PM
07:55AM
07:35AM
Loading…
Apr-29-26 07:35AM
06:53AM
Apr-28-26 08:01AM
Apr-16-26 04:05PM
04:05PM
Apr-09-26 04:25PM
02:34PM
Apr-07-26 08:05AM
Apr-02-26 08:00AM
Mar-25-26 04:15PM
12:49PM
Loading…
Mar-17-26 12:49PM
Mar-03-26 08:00AM
Feb-28-26 01:07AM
Feb-27-26 02:43AM
(New feeds test provider finance)
-26.58%
12:04AM
Feb-26-26 04:58PM
(Associated Press Finance)
04:05PM
04:01PM
04:01PM
Feb-13-26 07:55AM
Feb-12-26 06:00PM
09:02AM
Jan-16-26 10:26AM
07:46AM
06:24AM
01:08PM
Loading…
Jan-15-26 01:08PM
(The Wall Street Journal)
-12.68%
Jan-14-26 08:00AM
Jan-12-26 07:30AM
Jan-08-26 04:30PM
08:00AM
Jan-07-26 07:59AM
Dec-12-25 08:30AM
Dec-04-25 11:30AM
Nov-18-25 08:00AM
Nov-12-25 04:01PM
09:15AM
Nov-07-25 08:55AM
Oct-31-25 09:15AM
Oct-30-25 04:08PM
Oct-29-25 06:05PM
05:01PM
(Associated Press Finance)
04:15PM
Oct-28-25 08:00AM
Oct-08-25 07:45AM
Sep-24-25 04:05PM
02:05PM
Sep-19-25 08:34AM
Sep-15-25 08:35AM
Sep-09-25 12:10PM
(Pharmaceutical Technology)
+9.26%
07:30AM
Sep-02-25 07:40AM
Aug-29-25 08:05AM
Aug-27-25 08:01AM
Aug-21-25 08:45AM
Aug-18-25 09:45AM
Aug-07-25 10:16AM
Influenza Vaccine Market Research Report 2025-2030 Featuring GSK, Abbott, Pfizer, AstraZeneca, Sanofi, Moderna, CSL, Emergent BioSolutions, BIKEN, Serum Institute of India, Sinovac, GC Biopharma
(GlobeNewswire)
+36.65%
Aug-06-25 05:22PM
(Associated Press Finance)
04:15PM
Jul-28-25 08:50AM
08:50AM
Jul-15-25 07:30AM
Jul-08-25 04:45PM
Jul-02-25 04:05PM
Jun-23-25 08:05AM
Jun-20-25 08:13AM
Jun-05-25 07:00AM
May-29-25 09:55AM
May-19-25 09:43AM
May-16-25 10:52AM
May-14-25 07:32AM
May-08-25 09:53AM
(Thomson Reuters StreetEvents)
+34.18%
03:33AM
May-07-25 10:03PM
10:01PM
05:35PM
04:32PM
(Associated Press Finance)
04:05PM
May-01-25 05:07PM
Apr-22-25 08:00AM
Apr-10-25 09:52AM
Apr-09-25 08:45AM
Apr-08-25 12:24AM
Mar-31-25 08:00AM
Mar-26-25 10:32AM
Mar-20-25 04:30PM
08:30AM
08:06AM
Mar-19-25 05:01PM
04:30PM
Mar-18-25 08:00AM
Mar-13-25 11:00AM
(Pharmaceutical Technology)
-10.41%
08:29AM
Mar-12-25 08:00AM
Mar-10-25 09:14AM
Mar-04-25 06:59AM
(Thomson Reuters StreetEvents)
-6.44%
Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company's Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
SUJATA TYAGI DAYAL Director May 01 '26 Proposed Sale 8.40 13,761 115,612 May 01 04:20 PM KATHRYN ZOON Director May 01 '26 Proposed Sale 8.40 17,202 144,492 May 01 04:03 PM DONALD DEGOLYER Director May 01 '26 Proposed Sale 8.40 15,481 130,064 May 01 04:02 PM KEITH KATKIN Director Apr 30 '26 Proposed Sale 8.28 15,481 128,141 Apr 30 04:11 PM Williams Paul Anthony SVP, Products Business Apr 01 '26 Sale 8.44 4,000 33,760 62,681 Apr 03 04:05 PM PAUL WILLIAMS Officer Apr 01 '26 Proposed Sale 8.44 4,000 33,778 Apr 01 04:07 PM LOUIS W SULLIVAN Director Jan 07 '26 Proposed Sale 13.99 25,748 360,142 Jan 07 04:27 PM LOUIS W SULLIVAN Director Dec 22 '25 Proposed Sale 12.77 104,695 1,336,463 Dec 22 06:22 PM Richard Ronald Director Dec 05 '25 Option Exercise 5.02 25,748 129,255 124,165 Dec 09 06:01 PM Richard Ronald Director Dec 05 '25 Sale 11.97 21,984 263,077 98,417 Dec 09 06:01 PM RONALD RICHARD Director Dec 05 '25 Proposed Sale 11.94 32,848 392,335 Dec 05 04:04 PM DeGolyer Donald W Director Nov 10 '25 Sale 10.54 17,801 187,623 119,858 Nov 12 04:13 PM Dayal Sujata Tyagi Director Nov 07 '25 Sale 10.00 8,552 85,520 88,980 Nov 10 04:09 PM DONALD DEGOLYER Director Nov 10 '25 Proposed Sale 10.54 17,801 187,544 Nov 10 04:06 PM SUJATA TYAGI DAYAL Director Nov 07 '25 Proposed Sale 10.00 8,552 85,520 Nov 07 04:02 PM Glessner Coleen EVP, Quality & Ethics, and CPL Oct 07 '25 Sale 10.00 30,608 306,080 144,319 Oct 16 04:21 PM COLEEN GLESSNER Officer Oct 07 '25 Proposed Sale 10.00 30,608 306,080 Oct 07 04:11 PM Zoon Kathryn C Director Aug 15 '25 Sale 8.87 7,086 62,853 71,799 Aug 18 04:33 PM KATHRYN ZOON Director Aug 15 '25 Proposed Sale 8.87 7,086 62,853 Aug 15 04:04 PM DeGolyer Donald W Director Aug 12 '25 Sale 8.65 7,844 67,831 137,659 Aug 13 04:22 PM DONALD DEGOLYER Director Aug 12 '25 Proposed Sale 8.65 7,844 67,831 Aug 12 04:06 PM Katkin Keith Director May 23 '25 Sale 6.30 7,844 49,417 86,431 May 28 04:08 PM KEITH KATKIN Director May 23 '25 Proposed Sale 6.30 7,844 49,409 May 23 04:04 PM PAPA JOSEPH C President and CEO May 13 '25 Buy 5.83 60,000 349,800 342,500 May 15 04:02 PM
